Ubs Oncology Impact Fund L.P.
MPM BioImpact · adviser of record: MPM Asset Management LLC · 2014 vintage
Ubs Oncology Impact Fund L.P. is a 2014 venture fund managed by MPM BioImpact. It reported $570mm in gross assets at year-end 2025, against a peak of $1.19bn in 2020.
- Latest value held
- $570mm year-end 2025
- Peak
- $1.19bn year-end 2020
- Fund size
- Not on file
Value held by year-end
Gross asset value reported on Form ADV at each year-end. Open in the Fund Tracker
| Year-end | Gross assets | ÷ size | Change |
|---|---|---|---|
| 2025 | $570mm | – | -21% over 2 yrs |
| 2023 | $721mm | – | -8% |
| 2022 | $785mm | – | -21% |
| 2021 | $993mm | – | -17% |
| 2020 | $1.19bn | – | +54% |
| 2019 | $773mm | – | +22% |
| 2018 | $632mm | – | +82% |
| 2017 | $348mm | – | -26% |
| 2016 | $471mm | – | – |
| 2015 | $0k | – | – |
| 2014 | $0k | – | – |
Other funds from MPM BioImpact
- MPM Bioventures 2022, L.P. 2022
- Oncology Impact Fund 2, L.P. 2019
- MPM Bioventures 2018, L.P. 2017
- MPM Bioventures 2018 (B), L.P. 2017
- MPM Asset Management Investors BV2014 LLC 2017
- MPM Asset Management Investors BV2018 LLC 2017
- MPM Asset Management Investors BV5 LLC 2017
- MPM Asset Management Investors BV4 LLC 2017
- MPM Asset Management Investors Sunstates Fund LLC 2017
- MPM Asset Management Investors 2003 Bviii LLC 2017
- MPM Oncology Innovations Fund L.P. 2016
- MPM Bioventures 2014, L.P. 2014
About these numbers
Gross asset value is what the manager reports holding in the fund at each fiscal year-end, on SEC Form ADV, Schedule D. It includes the GP’s own commitment and is before carried interest, so it is not the LPs’ net return, and it does not show cash already distributed. A fall in value can mean distributions, markdowns or both. Fund size is the amount sold reported on Form D, which for some funds reflects only a first close. Private fund ID 805-4135349827. Data updated October 13, 2026.
Is this your fund?
Spot an error and email a correction. Facing DPI pressure? See how distribution financing works.